The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), Johnson & Johnson (Gold), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | Bexobrutideg shows durable activity in heavily pretreated CLL
Talha Munir, MBBS, MRCP, FRCPath, PhD, Leeds Teaching Hospitals NHS Trust, Leeds, UK, presents updated Phase Ia/b trial data on bexobrutideg in chronic lymphocytic leukemia (CLL), highlighting durable responses and encouraging progression-free survival in heavily pretreated patients previously exposed to BTK and BCL2 inhibitors. He also discusses the ongoing evaluation of this BTK degrader in earlier lines of therapy. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
